Ortoma Q4’23: First product sales - Redeye

Redeye provides a short comment on this morning’s Q4 report from Ortoma. The most important event in the report is the net sales figure, including sales of the company’s products for the first time. A one-time cost relating to earlier development no longer relevant in the current technical platform of SEK 24.3 held back the EBIT while not affecting cash flow. The liquid assets at the end of the quarter were a healthy SEK 51.4m. The Q4 continues to confirm the substantial progress even if the development over the quarters may be volatile as the company transitions from development to commercialization. We expect to make small changes to our estimates with a slight positive bias on our current Base case of SEK 14.5 per share.

Länk till analysen i sin helhet: https://www.redeye.se/research/982707/ortoma-q423-first-product-sales?utm_source=finwire&utm_medium=RSS